SWX

[SWX @StockWire_X]

Microba secures $3.06M R&D tax refund, boosting cash position to support gastrointestinal diagnostics and clinical therapeutics development @MicrobaLife $MAP

https://t.co/DT7Agllbrn

[SWX @StockWire_X]

Phoslock Environmental Technologies resumes production at its China facility in January 2026 after four years, driven by depleted inventory @PhoslockWater $PET

https://t.co/9AnefSBhB4

[SWX @StockWire_X]

Immuron secures US Department of Defense sub-award to develop oral therapeutics targeting military diarrhoea threats. @immuronltd $IMC

https://t.co/4qSywqrO0b

[SWX @StockWire_X]

@MicroequitiesAM delivers $1.9M November profit as Pure Microcap Value Fund drives strong performance, pushing 1H26 YTD to $5.3M. $MAM

https://t.co/mZlSf5fmaQ

[SWX @StockWire_X]

Kelly Partners climbs to 17th in AFR Top 100 Accounting Firms with $164.2M revenue run rate, now 82% of the way to cracking Top 10. $KPG

https://t.co/hT0RgX3rSP

[SWX @StockWire_X]

Mach7 secures first commercial Flamingo Architecture deployment with UnityPoint Health, generating A$0.6M ARR scaling to A$1.0M. $M7T

https://t.co/XxApB9lRXZ

[SWX @StockWire_X]

Avecho Biotechnology secures US and European patent allowances for its CBD TPM® soft-gel capsule, protecting the formulation until 2040. $AVE

https://t.co/RHWV5Z1BT8

[SWX @StockWire_X]

4DMedical secures major distribution partnership with Philips, guaranteeing A$15M minimum revenue across 2026-2027 for FDA-cleared CT:VQ™ technology. $4DX

https://t.co/lcj1ks4IsO

[SWX @StockWire_X]

OncoSil's OSPREY registry shows 20.6-22.0 month survival in pancreatic cancer patients vs 12.7-18.8 months for chemotherapy alone. $OSL

https://t.co/fBrA6GiKvP

[SWX @StockWire_X]

LTR Pharma secures ethics approval for SPONTAN Phase II erectile dysfunction study, with patient recruitment starting Q1 2026 and initial data expected Q2 2026. $LTP

https://t.co/XrYuQmOzJg

[SWX @StockWire_X]

Microba scores $3.06M R&D tax refund, boosting cash to ~$17M and extending runway for GI diagnostics and therapeutics without diluting shareholders @MicrobaLife $MAP

https://t.co/CbNBxrDYMY

[SWX @StockWire_X]

Invion secures perpetual global rights to Photosoft™ technology across $96.4B cancer markets via milestone-based share issuance. @InvionLimited $IVX

https://t.co/IpnvmGALba

[SWX @StockWire_X]

Phoslock Environmental Technologies restarts manufacturing at its China facility in January 2026, with initial capacity of 3,000 tonnes annually. @PhoslockEnviro $PET

https://t.co/IkSU2MhAPw

[SWX @StockWire_X]

Control Bionics acquires remaining 77.83% of Neuro Elite Athletics for US$389k, bringing EMG sports performance tech fully in-house. @ControlBionics $CBL

https://t.co/JJxu1UTEGn

[SWX @StockWire_X]

Island Pharmaceuticals secures $1M from insiders including Chairman Jason Carroll for Galidesivir antiviral programme, boosting cash to $7.91M. $ILA

https://t.co/jkZq0l5N1K

[SWX @StockWire_X]

BetMakers renews Penn Entertainment contract for 3 years with improved terms, boosting EBITDA by A$1.2M annually while adding 16 new Apollo customers. $BET

https://t.co/atv4UbXiLR

[SWX @StockWire_X]

Li-S Energy partners with UK defence contractor @MSubsLtd to test lithium-sulfur batteries for autonomous submarines, targeting Royal Navy programmes. $LIS

https://t.co/sbh1XE7MQN

[SWX @StockWire_X]

Amplia Therapeutics secures US patent grant for cancer drug narmafotinib, protecting its formulation until 2040 across major markets. $ATX

https://t.co/7iT118CnXo

[SWX @StockWire_X]

Optiscan Imaging launches pivotal head and neck cancer study at Perth hospital, with data set to support FDA submissions @OptiscanImaging $OIL

https://t.co/hhbT4wkrUi

[SWX @StockWire_X]

BCAL Diagnostics secures national ethics approval for landmark BREASTEST Registry, enrolling up to 24,000 women @BCALDxLtd $BDX

https://t.co/NfSbUOMEXs